Marsh & McLennan Companies, Inc.
MRSH · NYSE
Analyst ratings
buy · 14 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 13, 2026 | JP Morgan | Maintains | Overweight | $212.00 |
| July 10, 2026 | Evercore ISI Group | Maintains | Outperform | $234.00 |
| July 9, 2026 | Cantor Fitzgerald | Maintains | Overweight | $218.00 |
| July 9, 2026 | Mizuho | Maintains | Neutral | $197.00 |
| July 8, 2026 | UBS | Maintains | Buy | $212.00 |
| July 6, 2026 | Morgan Stanley | Maintains | Equal-Weight | $175.00 |
| June 9, 2026 | UBS | Maintains | Buy | $203.00 |
| May 26, 2026 | Piper Sandler | Maintains | Neutral | $182.00 |
| April 17, 2026 | Keefe, Bruyette & Woods | Maintains | Market Perform | $203.00 |
| April 14, 2026 | B of A Securities | Maintains | Underperform | $174.00 |
| April 13, 2026 | Mizuho | Maintains | Neutral | $193.00 |
| April 9, 2026 | JP Morgan | Maintains | Overweight | $206.00 |
| April 9, 2026 | Wells Fargo | Maintains | Equal-Weight | $178.00 |
| April 8, 2026 | Barclays | Maintains | Overweight | $206.00 |
| April 7, 2026 | Keefe, Bruyette & Woods | Maintains | Market Perform | $200.00 |
| April 6, 2026 | Morgan Stanley | Maintains | Equal-Weight | $190.00 |
| March 11, 2026 | Barclays | Maintains | Overweight | $209.00 |
| February 27, 2026 | Mizuho | Downgrades | Neutral | $199.00 |
| February 17, 2026 | Raymond James | Upgrades | Strong Buy | $225.00 |
| February 3, 2026 | Citigroup | Maintains | Neutral | $205.00 |
| February 2, 2026 | Keefe, Bruyette & Woods | Maintains | Market Perform | $206.00 |
| February 2, 2026 | Cantor Fitzgerald | Maintains | Overweight | $212.00 |
| January 30, 2026 | Morgan Stanley | Maintains | Equal-Weight | $195.00 |
| January 30, 2026 | RBC Capital | Reiterates | Sector Perform | $200.00 |
| January 30, 2026 | Wells Fargo | Maintains | Equal-Weight | $203.00 |
Valuation and stock upside potential
JPMorgan, UBS, and Evercore ISI maintain elevated price targets of $212, $212, and $234 respectively, arguing that Marsh & McLennan's fee-based revenue model, disciplined underwriting exposure, and strong pricing power in specialty markets justify a significant premium above current trading levels near $178.
BofA Securities maintains an Underperform rating with a price target of $178 — essentially at current market price — while Morgan Stanley trimmed its target to $175, both signaling the stock offers little to no upside and may be overvalued relative to near-term earnings prospects.
Near-term earnings growth trajectory
Marsh & McLennan reported Q1 EPS of $3.29, beating consensus estimates of $3.21 by $0.08, and research analysts forecast full-year EPS of $10.36, reflecting continued execution strength and resilient demand for risk advisory and consulting services.
Analysts project only single-digit earnings growth for Q2, and multiple firms including Piper Sandler and Morgan Stanley have recently trimmed their price targets, reflecting skepticism about the pace of earnings acceleration and the stock's ability to re-rate meaningfully higher.
Property insurance pricing headwinds and market conditions
Citigroup upgraded Marsh & McLennan from neutral to buy with a $200 target, and Cantor Fitzgerald raised its price objective to $218 with an overweight rating, reflecting confidence that the company's diversified revenue streams can offset sector-level pricing pressures.
RBC flagged that the U.S. insurance sector is set to face property pricing headwinds in Q2, a concern that could weigh on Marsh & McLennan's brokerage commissions and revenue growth, particularly given its exposure to commercial property lines.